Resistance Training Three Times a Week Can Offset Muscle Loss From Weight-Loss Drugs
A clinical trial published in November 2026 found that thrice-weekly resistance exercise can partially prevent the muscle loss associated with GLP-1 weight-loss drugs. Researchers say the findings offer a practical strategy for patients using obesity medications who want to preserve lean body mass.
A clinical trial published in November 2026 found that resistance exercise performed three times a week can partially offset the muscle loss that often accompanies the use of GLP-1 weight-loss drugs.
GLP-1 agonists, including drugs like semaglutide and tirzepatide, have become widely used for obesity treatment. While effective at reducing body weight, they can also cause patients to lose muscle mass along with fat, which raises concerns about long-term physical function and metabolic health.
The trial tested a structured weightlifting program in patients taking GLP-1 medications. Participants who completed three resistance training sessions per week retained significantly more lean muscle mass than those who did not exercise.
Researchers said the findings provide a clear, actionable recommendation for clinicians prescribing obesity drugs. Adding a resistance training component to treatment plans may help patients maintain strength and physical function as they lose weight.
The study was published in the journal Nature and adds to a growing body of evidence on how exercise can complement pharmacological obesity treatment.
Experts noted that the combination of medication and structured exercise may produce better long-term outcomes than either approach alone, particularly for older adults who are more vulnerable to muscle loss.

